"TP53, KRAS , and BRAF mutations were additionally independently associated with poor prognosis, although the association with BRAF and KRAS was restricted to MSI-negative tumours."
"CRC molecular features including MSI, CIMP and mutations in BRAF , KRAS and TP53 were not associated with age-adjusted cRTL or cRTL:nRTL ratios (multivariate P>0.115 for all comparisons) (Table xref )."
"However, p53, B-Raf V600E and K-Ras G13D proved dispensable for drug’s cytotoxic activity, thus rendering 3-BrPA a powerful therapeutic tool for the successful management of urothelial bladder tumors carrying either wild-type or mutant p53, B-Raf or K-Ras oncogenic forms."
"TP53, BRAF, and KRAS mutations are associated with differential lncRNA expression."
"For example, P53, KRAS, or BRAF mutations in metastatic colorectal cancer did not associate with bevacizumab-chemotherapy treatment outcome in metastatic colorectal cancer [ xref ]."
"In multivariable analysis incorporating known clinicopathological prognostic factors, we showed that low overall mutation burden and mutations in KRAS, BRAF , and TP53 were independently associated with decreased relapse-free survival after colorectal cancer treated with curative intent."
"Furthermore, mutations in p53, K-Ras and BRAF are associated with the neoplastic changes of IECs during the sporadic colon cancer development; BRAF and K-Ras mutations have been considered as prognostic markers for MSI ( xref )."